COVID-19 vaccination and diabetic ketoacidosis

An efficient coronavirus disease 2019 (COVID-19) vaccine is urgently required to fight the pandemic due to its high transmission rate and quick dissemination. There have been numerous reports on the side effects of the COVID-19 immu-nization, with a focus on its negative effects. Clinical endocrinology is extremely interested in the endocrine issue that arises after receiving the COVID-19 vaccine. As was already mentioned, after receiving the COVID-19 vaccine, many clinical problems could occur. Additionally, there are some compelling reports on diabetes. After receiving the COVID-19 vaccine, a patient experienced hyperosmolar hyperglycemia state, a case of newly-onset type 2 diabetes. There has also been information on a potential connection between the COVID-19 vaccine and diabetic ketoacidosis. Common symptoms include thirst, polydipsia, polyuria, palpitations, a lack of appetite, and weariness. In extremely rare clinical circumstances, a COVID-19 vaccine recipient may develop diabetes complications such as hyperglycemia and ketoacidosis. In these circumstances, routine clinical care has a successful track record. It is advised to give vaccine recipients who are vulnerable to problems, such as those with type 1 diabetes as an underlying illness, extra attention.

Effect of SARS-CoV-2 infection on trauma throughput to alternative elective care approaches

In response to the paper on coronavirus disease 2019's effects on trauma throughput, elective care models should be modified. Concerns about the relevant factors and their potential therapeutic applications are brought up and looked into.

Adipocytokine profile in children with Kawasaki disease

This letter to editor discusses on the publication on adipocytokine profile in children with Kawasaki disease. Concerns on confounding factors are raised and discussed.

Comment to: Disseminated cutaneous herpes simplex, COVID-19 vaccination and rheumatoid arthritis patient: a case report and review

Not available.

Immunoglobulin G4 associated autoimmune cholangitis and pancreatitis and nivolumab

This letter to editor discussing on the publication on immunoglobulin G4 associated autoimmune cholangitis and pancreatitis following the administration of nivolumab. Concerns on confounding factors are raised and discussed.

COVID-19 lockdown and increased incidence of dengue: A note

COVID-19 is the important global problem. Lockdown is a general disease control measure against COVID-19. The aim of lockdown is the reduce incidence of COVID-19. From reappraisal on the available data from a tropical endemic country (1), the change of incidences of both COVID-19 and rotavirus infection incidence after lockdown can be seen.

Clinical biomedical research of indoleamine 2,3-dioxygenase: update on current available reports from Southeast Asia

Indoleamine 2,3-dioxygenase is an important enzyme in human, which plays roles in the rate-limiting first step in tryptophan catabolism. Indoleamine 2,3-dioxygenase is currently studied by research groups worldwide. Association between Indoleamine 2,3-dioxygenase and medial disorders in clinical medicine is proposed and is an interesting topic in clinical biochemical reasearch. Here, the author briefly reviews and discusses on the available important scientific reports on Indoleamine 2,3-dioxygenase from tropical Southeast Asia.

Change of blood viscosity after COVID-19 vaccination: estimation for persons with underlying metabolic syndrome

The COVID-19 vaccine is a new vaccine aiming at control of COVID-19 pandemic. This new vaccine is useful for pandemic management, however, an important consideration is on its safety. Thrombosis is a problem might occur after COVID-19 vaccination and the increased blood viscosity is a pathomechanism. Here, the authors estimate on blood viscosity change after COVID-19 vaccination for vaccine recipient with underlying metabolic syndrome. Based on mathematical modelling and simulating technique, the authors estimate the change of blood viscosity after COVID-19 vaccination for persons with underlying metabolic syndrome. According to the estimation, blood viscosity in a healthy person is estimated 2.7 times higher than the normal value while blood viscosity in person with the underlying metabolic syndrome is estimated 2.99 times higher than the normal value. Based on this preliminary report, a more increased blood viscosity level is detected in vaccine recipients with the underlying metabolic syndrome. Monitoring of the blood viscosity problem among a vaccine recipient who has metabolic syndrome is recommended.